
    
      An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and
      Tolerability of Gefitinib 250 mg (IRESSAâ„¢) as First line Treatment in Caucasian Patients, who
      have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic
      Non-Small Cell Lung Cancer
    
  